Cargando…
The neuropsychopharmacology of cannabis: A review of human imaging studies
The laws governing cannabis are evolving worldwide and associated with changing patterns of use. The main psychoactive drug in cannabis is Δ(9)-tetrahydrocannabinol (THC), a partial agonist at the endocannabinoid CB(1) receptor. Acutely, cannabis and THC produce a range of effects on several neuroco...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Pergamon Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416743/ https://www.ncbi.nlm.nih.gov/pubmed/30347211 http://dx.doi.org/10.1016/j.pharmthera.2018.10.006 |
_version_ | 1783403419460960256 |
---|---|
author | Bloomfield, Michael A.P. Hindocha, Chandni Green, Sebastian F. Wall, Matthew B. Lees, Rachel Petrilli, Katherine Costello, Harry Ogunbiyi, M. Olabisi Bossong, Matthijs G. Freeman, Tom P. |
author_facet | Bloomfield, Michael A.P. Hindocha, Chandni Green, Sebastian F. Wall, Matthew B. Lees, Rachel Petrilli, Katherine Costello, Harry Ogunbiyi, M. Olabisi Bossong, Matthijs G. Freeman, Tom P. |
author_sort | Bloomfield, Michael A.P. |
collection | PubMed |
description | The laws governing cannabis are evolving worldwide and associated with changing patterns of use. The main psychoactive drug in cannabis is Δ(9)-tetrahydrocannabinol (THC), a partial agonist at the endocannabinoid CB(1) receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of cannabis, may offset some of these acute effects. Heavy repeated cannabis use, particularly during adolescence, has been associated with adverse effects on these systems, which increase the risk of mental illnesses including addiction and psychosis. Here, we provide a comprehensive state of the art review on the acute and chronic neuropsychopharmacology of cannabis by synthesizing the available neuroimaging research in humans. We describe the effects of drug exposure during development, implications for understanding psychosis and cannabis use disorder, and methodological considerations. Greater understanding of the precise mechanisms underlying the effects of cannabis may also give rise to new treatment targets. |
format | Online Article Text |
id | pubmed-6416743 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Pergamon Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-64167432019-03-26 The neuropsychopharmacology of cannabis: A review of human imaging studies Bloomfield, Michael A.P. Hindocha, Chandni Green, Sebastian F. Wall, Matthew B. Lees, Rachel Petrilli, Katherine Costello, Harry Ogunbiyi, M. Olabisi Bossong, Matthijs G. Freeman, Tom P. Pharmacol Ther Article The laws governing cannabis are evolving worldwide and associated with changing patterns of use. The main psychoactive drug in cannabis is Δ(9)-tetrahydrocannabinol (THC), a partial agonist at the endocannabinoid CB(1) receptor. Acutely, cannabis and THC produce a range of effects on several neurocognitive and pharmacological systems. These include effects on executive, emotional, reward and memory processing via direct interactions with the endocannabinoid system and indirect effects on the glutamatergic, GABAergic and dopaminergic systems. Cannabidiol, a non-intoxicating cannabinoid found in some forms of cannabis, may offset some of these acute effects. Heavy repeated cannabis use, particularly during adolescence, has been associated with adverse effects on these systems, which increase the risk of mental illnesses including addiction and psychosis. Here, we provide a comprehensive state of the art review on the acute and chronic neuropsychopharmacology of cannabis by synthesizing the available neuroimaging research in humans. We describe the effects of drug exposure during development, implications for understanding psychosis and cannabis use disorder, and methodological considerations. Greater understanding of the precise mechanisms underlying the effects of cannabis may also give rise to new treatment targets. Pergamon Press 2019-03 /pmc/articles/PMC6416743/ /pubmed/30347211 http://dx.doi.org/10.1016/j.pharmthera.2018.10.006 Text en © 2018 The Authors http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Bloomfield, Michael A.P. Hindocha, Chandni Green, Sebastian F. Wall, Matthew B. Lees, Rachel Petrilli, Katherine Costello, Harry Ogunbiyi, M. Olabisi Bossong, Matthijs G. Freeman, Tom P. The neuropsychopharmacology of cannabis: A review of human imaging studies |
title | The neuropsychopharmacology of cannabis: A review of human imaging studies |
title_full | The neuropsychopharmacology of cannabis: A review of human imaging studies |
title_fullStr | The neuropsychopharmacology of cannabis: A review of human imaging studies |
title_full_unstemmed | The neuropsychopharmacology of cannabis: A review of human imaging studies |
title_short | The neuropsychopharmacology of cannabis: A review of human imaging studies |
title_sort | neuropsychopharmacology of cannabis: a review of human imaging studies |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416743/ https://www.ncbi.nlm.nih.gov/pubmed/30347211 http://dx.doi.org/10.1016/j.pharmthera.2018.10.006 |
work_keys_str_mv | AT bloomfieldmichaelap theneuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT hindochachandni theneuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT greensebastianf theneuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT wallmatthewb theneuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT leesrachel theneuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT petrillikatherine theneuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT costelloharry theneuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT ogunbiyimolabisi theneuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT bossongmatthijsg theneuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT freemantomp theneuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT bloomfieldmichaelap neuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT hindochachandni neuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT greensebastianf neuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT wallmatthewb neuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT leesrachel neuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT petrillikatherine neuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT costelloharry neuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT ogunbiyimolabisi neuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT bossongmatthijsg neuropsychopharmacologyofcannabisareviewofhumanimagingstudies AT freemantomp neuropsychopharmacologyofcannabisareviewofhumanimagingstudies |